Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyvalent mechanical bacterial lysate is Lallemand Pharma's standardized, sublingual immunostimulant active ingredient, consisting of antigenic material from 13 strains of heat-inactivated respiratory bacterial pathogens that are mechanically disrupted by high-pressure lysis. The manufacturing approach is intended to preserve particulate bacterial antigens and promote mucosal and systemic immune responses, including immune surveillance and defense against recurrent respiratory infections. It is marketed under country-specific brands including Ismigen, Immubron, Respibron, PIR-05, and Pulmigen. ([lallemandpharma.com](https://www.lallemandpharma.com/production/polyvalent-mechanical-bacterial-lysate/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyvalent mechanical bacterial lysate.